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Abstract 
Leishmaniasis is a vector born disease identified by WHO as a globally neglected health 
problem. With 310 million people living at risk, there are an estimated 1.3 million new cases and 
30-40 thousand deaths occurring annually. Current chemotherapeutics are limited by toxicity, 
cost, deliverability, patient compliance, and emergence of resistance. In an attempt to discover 
novel antileishmanials, the Kinghorn group isolated several biologically active compounds from 
the hexane extracts of the roots of Pentalinon andrieuxii. The roots have historically been used to 
alleviate skin ulcers formed by cutaneous leishmaniasis. Among the isolated compounds was 
pentalinonsterol which has proven to be a compelling new target molecule for the treatment of 
leishmaniasis.  Synthetic preparation and route optimization of pentalinonsterol has facilitated 
further in vitro and in vivo studies as well as analogue synthesis for structure activity relationship 
(SAR) studies. An additional focus has been on 1) compound solubility, due to pentalinonsterol’s 
highly lipophilic nature necessitating liposomal encapsulation for in vivo studies (the results of 
which have reinforced the enthusiasm for this natural product as a potential chemotherapeutic for 
leishmaniasis), and 2) development of probes to study mechanism of action. The analogues in 
development will provide a “handle” for the attachment of water soluble functional groups 
through a pro-drug approach and also facilitate the generation of conjugates for use as 
mechanistic probes. Our current strategy has focused on introducing this handle, a hydroxyl 
moiety, onto the core of pentalinonsterol as this approach is likely to withstand the most 
variability in functionality, an idea supported by preliminary SAR studies suggesting the 
importance of A-ring and C17 side chain functionalization for activity. Further studies will 
hopefully lead to the development of a new drug that is more cost effective, more potent and less 
toxic than current antileishmanial drugs. 
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Chapter 1: Leishmaniasis 
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1.1 Parasitic Disease 
 
Leishmaniasis is a protozoan parasitic disease transferred by the female Phlebotomine sand-
fly vector.
1
 Its lifecycle is outlined in Figure 1.1 with two distinct 
life stages: promastigotes and amastigotes.  The flagellated 
promastigote is transferred from vector to host during the blood 
meal of the sandfly (>1000 per bite
2
).  Upon phagocytosis by the  
 
 
host’s macrophages, promastigotes undergo transformation into the amastigote stage.  Through 
binary fission they multiply and cause cell lysis, subsequently infecting other host macrophages.  
The lifecycle continues when a vector ingests a blood meal containing amastigote contaminated 
host macrophages.  Transformation back into promastigotes and multiplication takes place within 
the vector to complete the cycle.  Leishmaniasis is considered a zoonotic disease because it 
Sandfly blood meal 
Source: World Health Organization 
Figure 1.1. Leishmaniasis lifecycle.
 
Source: http://www.cdc.gov/parasites/leishmaniasis/biology.html 
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requires a mammalian host reservoir to remain endemic to a region.  No pathogenic response has 
been described for hosts other than dogs and humans.
2
   
                                
 
 
Figure 1.2. A variety of leishmaniasis species, their clinical manifestations, and affected regions.
3,4 
 
 
The resulting host infection is dependent on several factors including the parasite species 
and host immune response (which may contain the infection for weeks or even months before 
diagnostic abnormalities occur).
2
 There are three clinical manifestations of leishmaniasis: 
cutaneous, mucocutaneous, and visceral leishmaniasis.
1
 Cutaneous leishmaniasis (CL) is 
characterized by flat skin ulcers which feature slightly raised edges appearing on the host’s 
exposed skin where bitten. These ulcers are known to leave disfiguring scars and cause 
disability.  Visceral leishmaniasis (VL) is the deadliest clinical form of leishmaniasis.  It causes 
inflammation/swelling of internal organs (typically the spleen, liver, and bone marrow) the 
results of which are often fatal if left untreated. Mucocutaneous leishmaniasis (ML) is less 
common than the other two and is characterized by the spread of infection to the mucous 
Clinical Manifestation Leishmaniasis 
Species 
Region of distribution 
 
 
 
Cutaneous Leishmaniasis  
(oriental sore, tropical sore, uta ulcer, 
chiclero ulcer, or Aleppo boil) 
L. tropica Mediterranean countries, Afghanistan 
L. major Middle East, Western and Northern 
Africa, Kenya 
L. aethiopica Ethiopia 
L. mexicana Central America, Amazon regions 
Mucocutaneous Leishmaniasis 
(espundia) 
L. braziliensis Brazil, Peru, Ecuador, Columbia, 
Venezuela 
 
Visceral Leishmaniais 
(kala-azar, dumdum fever,  
or black fever) 
L. donovani China, India, Iran, Sudan, Kenya, 
Ethiopia 
L. infantum Mediterranean countries 
L. chagasi Brazil, Columbia, Venezuela, Argentina 
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membranes located around the ear, nose, and throat leaving the host mutilated.  It is preventable 
by treatment of the original CL infection.  Leishmaniasis species responsible for VL can thrive at 
core body temperatures (thus the internal organ infection) while those responsible for CL survive 
best at cooler peripheral temperatures (skin ulcers etc.).
2
 These different manifestations, 
therefore, ultimately arise from localization due to the temperature dependence of various 
parasite species.  
 
 
1.2 Demographics 
 
According to information provided by the Center for Disease Control and Prevention (CDC) 
and the World Health Organization (WHO), there are 310 million people living at risk of 
leishmaniasis.
1
 An estimated 1.3 million new cases and an upwards of 40 thousand deaths occur 
annually with approximately 12 million infected at any given time.
5
 Figure 1.3, A and B, 
contains information regarding the number of new cases of CL and VL, respectively, reported in 
the year 2012.  The figure also provides a rough outline of endemic regions showing their 
location within primarily tropical climates.  The numbers reported are likely underestimated due 
to the remoteness of poverty stricken locations afflicted by leishmaniasis and unreported cases of 
death by visceral leishmaniasis.
5
  WHO has identified leishmaniasis as a globally neglected 
health problem due to the severe lack of information regarding incidents of the disease as well as 
the lack of funding and medical facilities for treatment in endemic regions.
1
  The disease will 
spread with its vector, therefore more regions are at risk as global warming increases the range of 
the phlebotomine sandfly.
6
  In immunosuppressed individuals, such as patients co-infected with 
HIV, leishmaniasis acts as an opportunistic disease further complicating treatment.
7 
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Figure 1.3. The number of new cases of CL (A) and VL (B) reported in 2012
1 
 
A 
B 
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1.3 Current Antileishmanials 
 
Figure 1.4. Current widely used chemotherapeutics for the treatment of leishmaniasis.
8 
 
Pentavalent antimonials have been the conventional chemotherapeutic regimen for over 75 
years and remain the go-to drugs for the treatment of leishmaniasis around the world.
8
  However, 
significant resistance (60% of VL patients in Bihar-India) has begun showing up since 1970 in 
both India and Sudan.
8
  Other limitations of these antimonials include the need for intramuscular 
administration for up to 1 month long treatments and the severe cardiac, hepatic, pancreatic, and 
renal side effects associated with their use.  Amphotericin B requires intravenous administration 
and is associated with renal toxicity, a problem that is reduced upon liposomal encapsulation, the 
cost of which drastically limits its practicality for use in undeveloped countries.  Miltefosine is 
the first and still the only orally available treatment against leishmaniasis.  Its side effects are 
mild compared to the other choices and it represents movement in the right direction for 
leishmaniasis treatments.   
Each drug compound relies on target specificity which may only be effective against specific 
species of the leishmania parasite due to genetic differences.  The existence of over 20 
7 
 
leishmania species makes it difficult to find a treatment that would be effective against all forms 
of the disease.  Low patient compliance, due to administration methods and lack of proper 
healthcare systems, heightens the chance of resistance development in endemic regions.  There is 
a high need for a diverse set of new treatments which address the concerns of high toxicity, high 
cost, and oral availability.  
 
1.4 Methodology Introduction 
 
Our approach to finding new potential antileishmanial chemotherapeutics is one based on 
collaborative efforts which require reciprocal communication.  Bioassay guided fractionation is 
 
used to identify biologically active plant extracts.  Following structure elucidation of isolated 
compounds, the biological activity of each individual compound is determined.  Active isolates 
provide various leads for synthetic development which is generally required to facilitate more 
thorough biological studies of the parent molecule.  A robust synthetic strategy then allows 
analogue development for structure activity relationship (SAR) and mechanism of action studies.   
The idea is that back and forth work/communication between the biology and chemistry labs will 
eventually lead to a selectively potent new chemotherapeutic. 
While there exists a lot of potential for natural product antileishmanials as seen by various 
reports of active plant extracts, no natural products have yet to become available for the 
treatment of leishmaniasis.
8,9
  Natural products present a source of compounds with structurally 
8 
 
unique scaffolds and non-precedented activities that could provide interesting leads for the 
treatment of leishmaniasis.  
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Chapter 2: Isolation and Preliminary Biological Studies of Pentalinonsterol 
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A collaboration between Dr. Douglas Kinghorn (natural product isolation chemistry - OSU), 
Dr. Abhay Satoskar (immunology and leishmaniasis - OSU), and Dr. James Fuchs 
(synthetic/medicinal chemistry - OSU) has provided a great opportunity for acquiring inspiration 
for antileishmanials from natural products.  Of several plant species native to the Yucatan 
Peninsula of Mexico investigated for their antileishmanial properties, Pentalinon andrieuxii 
exhibited the most potential due to the observed activity of the crude extracts as well as its 
 
reported use in the region.  Interestingly, the roots of P. andrieuxii (found specifically in 
Campeche, Mexico) have been used in traditional Mayan medicine to treat CL lesions via daily 
cleansing of the wound with a root-based infusion followed by binding of the skin ulcer with the 
inner-root until visibly gone.
10,11 
 Activity guided fractionation identified the hexane-soluble extract of the roots of Pentalinon 
andrieuxii as the most potent crude extract with an IC50 of 35 mg/mL against promastigotes of L. 
mexicana.
12
 A topical application of the hexane Pentalinon andrieuxii root extract (PARE) were 
shown to visibly reduce the number of parasite containing macrophages present in the ear dermis 
of C57BL/6 mice infected with L. mexicana. Figure 2.2 shows a decrease of infected 
macrophages upon treatment with PARE (left) as compared to the control (right) with the red 
Figure 2.1. Air dried roots of P. andrieuxii (Photo: Y. Deng) 
11 
 
arrows pointing at examples of highly infected macrophages characterized by observable 
parasites (small black dots).  
 
 
Figure 2.2. Stained sections of L. mexicana infected mouse ear following 21 days of application with a solution 
of 10 µg PARE dissolved in 50 µL of DMSO/PBS (unpublished work from the Satoskar lab). 
 
 
Isolation and structure elucidation of the compounds contained within the hexane-soluble 
extract was accomplished in the Kinghorn Lab by Dr. Li Pan.  Of the 20 compounds isolated 
from PARE (shown in Figure 2.3), biological evaluation determined the six outlined in red to be 
the most active.  The active compounds can be split into three sterol structural classes:  
I. A-ring -unsaturated ketone 
II. -ring -unsaturated alcohol 
III. D-ring -unsaturated methyl ketone  
Classes II and III have been pursued independently by other members in our lab.  Oxidized 
cholesterol (3) belongs to the first class and exhibits nanomolar activity against L. mexicana 
amastigotes.  However, it shows little potential for chemical optimization.  The focus of this  
12 
 
 
Figure 2.3. Compounds isolated from the hexane-soluble extract of P. andrieuxii  
 
 
 
 
 
Figure 2.4. In vitro antileishmanial activity.  IC50 values
12
 in μM; anything greater than 100 μM is considered 
to be inactive which is the case for isolated compounds not listed in the figure. *Pentostam, also known as 
sodium stibogluconate, is an antimonial chemotherapeutic currently used for the treatment of leishmaniasis 
and was used as a reference standard in this experiment. 
Compound      L. mexicana 
       Promastigotes Amastigotes  
-------------------------------------------------------------------------------------------------------------- 
pentalinonsterol (1)      30.0   3.3 
2        24.0   3.5  
3        81.0            0.03 
4                 > 262            14.5 
dihydroneridienone (5)       9.2   1.4 
neridienone (6)      26.2   3.5  
Pentostam*                346.1   2.7 
 
 
1 
2 
3 
4 
5 
6 
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thesis is on the biologically active class I compound, pentalinonsterol (1), which represents a 
synthetically feasible novel target that offers a greater opportunity for optimization.   
 Pentalinonsterol (1) and compounds 2, 3, 5, and 6 all possess the same A-ring oxidation state, 
which may contribute to their comparable IC50 values (Figure 2.4).  Compound 4 lacks the same 
A-ring oxidation and yet was the only isolate besides 1, 2, 3, 5, and 6 that exhibited 
antileishmanial activity against amastigotes, albeit with lower relative potency.  Closer 
inspection revealed that pentalinonsterol and compound 4 both have the same C17 side chain, 
possibly attributing this particular side chain to the activity of compound 4.  The absence of 
activity from compounds with extensively branched chains provides further evidence for the 
importance of this C17 chain.  Thus, preliminary SAR investigation has identified the A-ring 
α,β-unsaturated ketone and the C17 side chain incorporating a prenyl group as the possible 
pharmacophore for the antileishmanial activity of pentalinonsterol (1). 
 
 Upon treatment with pentalinonsterol (1), parasitic promastigotes exhibited destructive 
membrane alterations (Figure 2.5 - C), more so than the reference sodium stibogluconate.  In 
vitro activity against both promastigote and amastigote forms of the L. mexicana leishmania 
A C B 
Figure 2.5. Electron microscopy of L. mexicana  promastigotes.
12
  A: untreated control; B: treated with 
pentostam (SSG-100 µM); C: treated with pentalinonsterol (100 µM) 
14 
 
parasite has proven the novel compound, pentalinonsterol (1), to be a potential new target 
molecule for the chemotherapeutic treatment of leishmaniasis.    The desire for larger quantities 
(1.2 mg was isolated from 900 g of dried roots) to facilitate further biological studies led to the 
synthetic development of pentalinonsterol by our group. 
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Chapter 3: Synthesis of Pentalinonsterol and Structurally Similar Analogues 
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3.1 Synthetic Approach 
Figure 3.1. Dr. Abdelhamid’s reaction scheme.4 
 
 The amount of natural product isolated from the dried roots of Pentalinon andrieuxii (1.2 mg 
from 900 g) limited the biological testing that could initially be performed on pentalinonsterol.  
As a novel chemical compound and one of the most active of the isolated sterols, it was 
considered an important synthetic target as additional material could facilitate thorough 
biological testing including structure activity relationship (SAR) and mechanism of action 
(MOA) studies.  The synthesis of pentalinonsterol was initially achieved by Dr. Dalia 
Abdelhamid (Figure 3.1), a previous graduate student from the Fuchs lab, as part of her 
dissertation.  The use of pregnenolone as the starting material allowed the semi-synthesis of 
pentalinonsterol in just five steps.  First the A-ring alcohol was protected with a silyl group in 
order to limit reactivity of this position during the following steps.  The C17 methyl ketone then 
provided quick access to the side chain via a key alkylation step which required an investigation 
of conditions.  Dr. Abdelhamid worked out the conditions to afford an appreciable yield of 78% 
using the bulky base lithiumdiosoproplyamide (LDA) to favor kinetic enolate formation along 
with the charge separator hexamethylphosphoramide (HMPA) to make it more reactive towards 
the alkylating reagent.  Initial failed attempts at acquiring the desired C18 methylene using the 
17 
 
Wittig reaction led to utilization of the Tebbe reagent for a 58% yield of the olefinated product.  
Deprotection of the A-ring protected alcohol proceeded in quantitative yield using 
tetrabutylammonium fluoride (TBAF) as the fluoride source.  Implementation of the Oppenhauer 
oxidation as reported by Uskokovic et al. provided Dr. Abdelhamid with a mixture of tautomers 
indicating incomplete olefin isomerization following the alcohol oxidation.
13
 Reich et al. 
previously reported the use of N-methylpiperidone instead of cyclohexanone as the hydride 
acceptor for the Oppenhauer oxidation of pregnenolone (the starting material for the 
pentalinonsterol synthesis).
14
 Dr. Abdelhamid’s use of N-methylpiperidone afforded 
pentalinonsterol from the unsaturated alcohol in 88% yield.   
 
Figure 3.2. Optimized pentalinonsterol synthesis 
 
 While working towards multi-gram quantities of the product for additional biological studies, 
optimization of the synthetic sequence was performed during the summer of 2013.  Minor 
changes were made to Dr. Abdelhamid’s sequence which afforded an increased overall yield 
from twenty-five percent to forty-seven percent while decreasing the need for purification of 
intermediates and reagent cost.  Figure 3.2 displays an overlay of the optimized sequence 
18 
 
(outlined in red) with Dr. Abdelhamid’s (outlined in black).  Specific examples of optimization 
include: 
 avoiding use of the carcinogenic charge separator HMPA in the alkylation  
 co-isolation of mono- and di-alkylated product (to be resolved upon alcohol 
deprotection) due to separation complications following alkylation  
 successful implementation of Wittig olefination over the more expensive Tebbe reagent 
 hexane trituration of olefination product 
 successful Oppenhauer oxidation with subsequent tautomerization using cyclohexanone 
rather than the more expensive N-methylpiperidone as the hydride acceptor 
Wanting to avoid the use of carcinogenic HMPA led to the use of lithium tetramethylpiperidide 
(LiTMP) over LDA for kinetic enolate formation.  Although pure materials were isolated at this 
stage for yield determination, it was demonstrated that co-isolation of both mono- and di-
alkylated products (requiring less time and smaller quantities of solvent) generated in the 
alkylation reaction could efficiently be carried through the olefination step and deprotection 
reaction with an increase in overall yield since material was typically lost during purification.  
The increased polarity of the compounds upon deprotection of the silyl protected alcohol made 
“late-stage” separation of these products much easier.  In the olefination step, excess Wittig 
reagent (approximately 10 equivalents) was found to afford a good yield, both giving more 
product and costing less than materials required for the Tebbe methylenation.  Following 
quantitative deprotection of the silyl protected alcohol, an Oppenhauer oxidation was utilized to 
introduce the A ring oxidation state.  The use of cyclohexanone as a cheaper alternative to N-
methylpiperidone afforded us the -unsaturated ketone as the only isomer in similar yields to 
Dr. Abdelhamid.  N-methylpiperidone was reported by Reich et al. as an easily extractable 
19 
 
(water soluble upon protonation) alternative to excess cyclohexanone in the reaction mixture.
14
  
However, in this case there was no trouble in isolating pentalinonsterol from cyclohexanone 
using conventional flash chromatography.  The complete isomerization to the -unsaturated 
ketone is believed to be the thermodynamic result of extended reaction times.  
 Having facilitated further biological studies of pentalinonsterol through the preparation of 
gram quantities of the natural product, interest in the compound shifted toward production of 
analogues of this natural product in an effort to explore and improve its pharmacological 
properties.  This first round of analogues focused on the importance of the predetermined 
pharmacophore.  A-ring analogues 12 and 13 were acquired through the post-synthetic 
manipulation of pentalinonsterol.  A Luche reduction of the C3 ketone yielded both epimers of  
 
Figure 3.3. Library of analogues to date. 
 
the resulting allyl alcohol while a DDQ oxidation yielded the oxidized 1,4-dienone product of 
pentalinonsterol (not shown) which proved to be unstable.  The rationale behind these analogues 
was to probe the true importance of the A-ring oxidation state via changes in polarity and 
hydrogen bond donor/acceptor capabilities which have an impact on binding interactions and 
drug properties.  Variation of the alkylating reagent in the synthetic sequence en route to 
pentalinonsterol led to C17 side chain analogues while omission of the Wittig olefination led to 
20 
 
C18 ketone analogues of pentalinonsterol.  The rationale behind these C17 side chain analogues 
(15-17 prepared by Robert Demoret) is to probe the importance of the length, substitution, and 
oxidation state of this chain as this might affect binding within a particular enzyme pocket. 
 
3.2 Biological Studies Facilitated by Synthetic Production of Pentalinonsterol 
  
Promising results have been obtained from in vivo and in vitro studies of synthetically 
prepared pentalinonsterol (PEN) suggesting that its activity can be attributed to multiple 
mechanisms of action.  In collaboration with the Ainslie and Satoskar labs, in vivo results with  
 
  
 
encapsulated PEN revealed amastigote load reduction in the spleen (Figure 3.4 - 83% 
reduction), liver (64%), and bone marrow (57%) of mouse hosts with respect to an empty 
liposome control. Comparatively, a conventional chemotherapeutic sodium stibogluconate (SSG) 
showed low clearance at a 28 times greater concentration.  Bone marrow amastigote reduction is 
key to eradication of VL due to its ability to act as a parasite reservoir.  Elevated levels of ALT 
and AST liver enzymes induce cell necrosis and thus represent markers for cytotoxicity of 
Figure 3.4. In vivo results following treatment of L. donovani infected mice with encapsulated 
pentalinonsterol (encapsulation by the Ainslie Lab).
15 
21 
 
compounds.
16
  Levels of these enzymes relative to control suggest that encapsulated PEN was 
well tolerated by the mice.
17
  An MTT assay performed with non-encapsulated pentalinonsterol 
also showed high cell viability and therefore low toxicity associated with doses of 25 and 50 µM. 
 
In studies on pentalinonsterol, carried out in the Parinandi lab, a dose-dependent decrease in 
fatty acid composition of L. donovani promastigotes was observed (Figure 3.5), suggesting that 
some of PEN’s activity is attributed to the breakdown of phospholipids in the parasite’s 
membrane - possibly through activation of phospholipases A1 and A2.  Physical evidence of this 
mechanism of action was seen previously during preliminary in vitro studies where alterations to 
a promastigote membrane were seen following treatment with pentalinonsterol (Figure 2.5).  
Minimal discrepancy in fatty acid composition suggests pentalinonsterol’s potential for efficacy 
against multiple species.  
An observed increase in mature and parasite free hepatic granuloma following treatment with 
encapsulated pentalinonsterol as well as increased T cell proliferation indicate an induced host 
immune response via increase in IFN- and IL-12 release.  Formation of mature hepatic 
Figure 3.5. Fatty acid composition of L. donovani promastigotes after treatment with PEN (Parinandi Lab).
15 
22 
 
granulomas as a result of increased IFN- release has previously been shown to contribute to 
reduction of amastigotes within the host, while in general increased IFN- and IL-12 release has 
been associated with various anti-parasitic immune responses including the observed formation 
of mature hepatic granuloma.
18,19,20,21
    
 
 
 
The observed pro-inflammatory cytokine response presented the idea of PEN as an adjuvant 
which prompted biological testing to determine how Figure 3.3 analogues (in vivo load 
reduction studies currently underway) affect IL-12 (Figure 3.6) and IL-10 (data not shown) 
release.   IL-10 levels were relative to the control for all compounds tested, thus demonstrating 
that this system does not promote an anti-inflammatory response. Pentalinonsterol is the most 
potent at promoting IL-12 release compared to its structural analogues to date, reinforcing the 
importance of the A-ring oxidation state and the C17 side chain.     However, improvement of its 
drug properties is required for consideration as an effective antileishmanial.  Pentalinonsterol’s 
lipophilic nature makes it difficult to introduce into a biological system without encapsulation 
which introduces an increased cost of production and requires intravenous administration.  
Figure 3.6. PEN and structurally related analogues effect on IL-12 release from bone marrow dendritic 
cells as measured by ELISA (Satoskar Lab; red bars added for clarity).
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Chapter 4: Hydroxyl Containing Analogues of Pentalinonsterol for Solubility Improvement 
and Mechanism of Action Studies 
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4.1 Addressing Solubility Issues 
 
 Pentalinonsterol is a very lipophilic molecule (logP = 6.29, ChemBioDraw Ultra version 14.0) 
which limits its water solubility, thus limiting its absorption into and transport throughout a 
biological system.  In medicinal chemistry, efforts are often made to attach polar functional 
groups onto a potential drug molecule to optimize drug properties and make drug delivery more 
feasible.  As shown previously, liposomal encapsulation facilitated in vivo studies of 
pentalinonsterol but required intravenous administration.  The ideal medication can be taken 
orally, requiring no trained medical attendants while simultaneously improving patient 
compliance.  The goal of this portion of the project, therefore, is to modify the existing synthetic 
route to pentalinonsterol by utilizing strategies employed in previous sterol syntheses to “install” 
a functionalizable hydroxyl group onto the core of pentalinonsterol in the hopes of increasing its 
water solubility using a pro-drug 
approach.  As noted above, it appears 
that the C17 side chain and the α,β-
unsaturated ketone on the A ring are 
necessary for the biological activity 
of pentalinonsterol.  Therefore, the 
proposed synthesis is focused on 
introducing a hydroxyl group onto the 
core ring system of pentalinonsterol 
which would be expected to tolerate 
more variability in functionality. 
Figure 4.1. Desired analogues  
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C12 and C7 are practical positions for the introduction of a hydroxyl group because of the 
choice of starting material.  Pregnenolone was the obvious starting material choice for the 
synthesis of pentalinonsterol as it could be transformed into the product in five simple organic 
reactions. The desired hydroxyl installment, however, cannot easily be accomplished on the 
sterol backbone of pregnenolone.  Deoxycholic acid (C12 hydroxyl) and chenodeoxycholic acid 
(C7 hydroxyl), naturally occurring bile acids structurally related to cholic acid, are commercially 
available starting materials that conveniently already possess a hydroxyl group at either of the 
two desired positions.  Because the newly introduced hydroxyl group may have an adverse effect 
on compound activity, assembling both regioisomeric analogues increases the probability that 
one will retain or exhibit improved activity.  The presence of a hydroxyl group should facilitate 
further functionalization of the molecule in order to improve solubility or prepare molecular 
probes.   
 
4.2 Analogue Development Methodology 
 
 
Figure 4.2. Retrosynthetic analysis of hydroxyl-pentalinonsterol analogues.  Reaction sequences were 
expected to be tolerated equally well by both deoxycholic and chenodeoxycholic acid. 
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 Although cholic acid derivatives provide a unique starting material for the synthesis of these 
hydroxyl containing pentalinonsterol analogues, their synthesis is not trivial. There is precedence 
by Barton et al. for the three step truncation of bile acid side chains to the methyl ketone in the 
presence of acetate protected alcohols on molecular systems very similar to both deoxycholic 
acid and chenodeoxycholic acid.
22
 At that stage, methodology similar to that reported by Dr. 
Abdelhamid/later optimized could be applied to introduce the required side chain functionality.
4
 
The next complication arises with respect to incorporation of the α,β-unsaturated ketone.  This 
requires a selective deprotection of the C3 hydroxyl substituent, reported on a similar system 
using acetate protecting groups by Geoffroy et al,
 
followed by an oxidation to give the C3 
ketone.
23
 The presence of the ketone moiety sets up the molecule for an IBX oxidation based on 
literature precedent which our lab has previously demonstrated, affording the final product after 
a simple deprotection of the C12 or C7 hydroxyl group.
24,25
  
 
4.3 Progress, to Date, Towards Hydroxyl Containing Analogues 
 
 
Figure 4.3. Our use of the Barton side chain truncation sequence on deoxycholic and chenodeoxycholic acid. 
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 The Barton et al. side chain truncation reaction sequence undergoes several unique 
mechanistic transformations.  Thionyl chloride is used to install a sulphine group alpha to an 
ester followed by conversion to -ketoester 30/31 which when treated with cupric acetate in the 
presence of atmospheric oxygen undergoes a three carbon truncation with the liberation of 2 
moles of carbon monoxide and 1 mol of carbon dioxide.
22
    Some drawbacks to the Barton side 
chain truncation are the low yielding sulfonation transformation when performed on our system 
as well as the 1.5 week reaction time for the conversion of 30/31 to 25/32.  Despite these 
drawbacks, this sequence has provided enough material to move forward with the synthesis of 
our hydroxyl-containing analogues.  Further optimization will be performed if one or more of the 
analogues require substantial biological investigation following initial studies.   
 Attempting the alkylation on compound 32 afforded six new spots by thin layer 
chromatography (TLC) indicating possible alkylation of the acetate protecting groups in addition 
to alkylation at the C17 methyl ketone.  Our previous synthesis of pentalinonsterol showed that 
the alkylation could be carried out in good yields in the presence of silyl ether protecting groups.  
Having determined that the side chain degradation cannot be performed in the presence of silyl 
protecting groups due to the acidic conditions required, the acetate protecting groups were 
exchanged for silyl ether protecting groups after obtaining the key methyl ketone intermediate.   
The alkylation of protected methyl ketone 35 (Figure 4.4) has been successfully performed 
on 30 mg scale to obtain mono- and di-alkylated products as noted by crude NMR.  The crude 
alkylation products were then subjected to Wittig conditions as described previously in the 
synthetic route to pentalinonsterol. The products of the reaction have not yet been isolated and 
interpretation of the crude NMR has not been conclusive.  It will be necessary to synthesize 
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larger quantities of compounds 25 and 32 to facilitate obtaining these intermediates in higher 
yields and allow further investigation of these reactions. 
 
 
Figure 4.4. Incorporation of pentalinonsterol synthesis 
 
4.4 Remaining Steps towards Hydroxyl Containing Analogues 
 
 
Figure 4.5. Remaining synthetic transformations. 
 
Incorporation of the A-ring unsaturated ketone will require some additional synthetic 
transformations.  We initially found precedence for the selective removal of the A-ring over the 
C-ring protecting group acetates.
23
  The acetate/silyl exchange of protecting groups brought on 
29 
 
the question of whether or not selective deprotection of the silyl group was plausible.  The 
secondary neopentyl C12 alcohol has proven to be a difficult steric obstacle for installing 
protecting groups as seen by the harsher conditions required for silyl protection.  Thus we were 
not surprised to find precedence for the selective deprotection of silyl groups as well.  A patent 
by O’Doherty et al. reports selective removal of the A-ring silyl protecting group over the C-
ring.
26
    There is no reported precedent, however, for similar selectivity over the B-ring hydroxyl 
present in the chenodeoxycholic derived hydroxyl analogue.  If the same reaction conditions do 
not selectively remove the A-ring and instead results in deprotection of both alcohols, we will 
follow the regioselective oxidation as reported by Li et al. to selectively install the C3 ketone 
following complete deprotection.
27
  IBX oxidation will then be utilized to afford the desired A-
ring oxidation state.
25 
 
4.5 Final Analogues for Solubility and MOA Studies 
 
 
 
Figure 4.6. Possible choices for prodrugs. 
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There are multiple options for increasing the water solubility of the desired hydroxyl-
analogues.  Our group has previously explored the use of phosphate groups as prodrug 
conjugates on unrelated projects, but other possibilities (Figure 4.6) include amino acids, 
carbohydrates, and succinates (not shown).  Dextran polymers as prodrugs have been 
investigated and accumulation selectivity depending on molecular weight of the dextran polymer 
conjugate has been reported.
28,29
  Zhang and Mehvar report liver and spleen target specificity 
using the dextran-70 prodrug of methylprednisolone (an immunosuppressive sterol used to 
prevent organ transplant rejection).
30
  Their rationale was to target the site of action, liver and 
spleen, which are two organs we wish to target due to accumulation of amastigotes in these 
organs with visceral leishmaniasis.  Figure 4.7 shows what the hydroxyl-analogue looks like 
with this prodrug compared to the methylprednisolone prodrug. 
 
 
Figure 4.7. Prodrug approach modelling work done by Zhang and Mehvar to target liver and spleen with the 
hopes of improving bioavailability as well.
 
 
 
Multiple syntheses of dextran macromolecule prodrugs have been reported with minor 
alterations over time using carbonyldiimidazole (CDI) for attaching the drug molecule to 
dextran-70 via the carboxylic acid substituents on either side of a succinate linker.
31,32
  Some 
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complications may arise due to the steric hindrance previously associated with the C12 hydroxyl 
analogue and so attachment at the C7 position might be more plausible.  Regardless, this prodrug 
approach represents a very interesting route towards improving not only solubility but delivery 
specificity as well. 
The introduction of a hydroxyl group onto the sterol backbone could be employed not only 
for the purposes of increasing solubility, but also to probe the mechanism of action of these 
compounds through linkage of the sterol to an affinity or fluorescent probe. Figure 4.8 depicts 
the attachment of biotin to the C7 hydroxyl PEN analogue.  A review by Katja Hubel, Toben  
  
Figure 4.8. Hydroxyl-containing analogue as a mechanistic probe. 
 
LeBmann, and Herbert Waldmann discusses use of biotin as a small molecule mechanistic 
probe.
33
 Following attachment, the analogue can be immobilized on beads covalently bound 
to streptavidin for which biotin has a high affinity.  A test cell is then lysed and combined with 
the immobilized small molecule in various pull down assays to identify the small molecule’s 
target protein(s).  A fluorescent attachment to the linker could facilitate easier identification of 
target proteins.  
Several examples of affinity based target protein identification experiments which could 
utilize a bead bound bioactive small molecule as depicted in Figure 4.9 are discussed in a review 
by Amanda McFedries, Adam Schwaid, and Alan Saghatelian.
34
  A particularly interesting 
experiment involved culturing “heavy” cells in media containing isotopic amino acids which end  
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Figure 4.9. Pull down assay experiment33 
 
up incorporated in cell’s protein.  The same proteins with lower mass are present in “light” cells.  
Lysates of both are incubated with the beads except that prior to incubation the light cell lysate is 
treated with a soluble form of the same small molecule which is attached to the bead to prevent 
attachment to the bead.  Bound proteins are eluted from the beads and combined following the 
removal of lysate.  The target proteins are then identified by increased ratio of heavy protein to 
light protein using quantitative proteomics.
35,36 
Successful use of coumarin analogues as fluorescent probes for natural products has been 
investigated by J. J. La Clair.
37
 The coumarin analogues were selected based on their ability to 
leave original activity and delivery unaffected.  Analogues 49 and 50, whose syntheses from 
compound 48 are outlined in the article, could be utilized with our prepared conjugates which 
contain hydroxyl handles for attachment via Mitsunobu or aziridine ring-opening as depicted in 
Figure 4.10.  LED fluorescence microscopy could then be used to identify localization of our 
compound. 
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Figure 4.10. Two proposed mechanistic probes inspired by work on reported natural product mechanistic 
conjugates.
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4.6 Concluding Remarks 
 
Successful isolation and structure elucidation of the active compounds within the hexane 
extracts of the roots of Pentalinon andrieuxii (Kinghorn group) provided a promising 
antileishmanial lead compound, pentalinonsterol.  Optimization of the previously reported 
synthetic route (Fuchs Group) towards pentalinonsterol has facilitated extensive biological 
studies (Satoskar, Parinandi, and Ainslie Groups) providing convincing evidence of 
pentalinonsterol’s antileishmanial properties.  Of importance was the identification of a dual 
mechanism of action in the eradication of leishmaniasis parasites through a combination of 
destructive membrane alterations and an induced host immune response.  Initial analogue 
development focused on probing the importance of the pre-determined pharmacophore, the A-
ring ,-unsaturated ketone and the C17 side chain, via structure-activity relationship studies.  
Non-comprehensive biological data gave evidence supporting the importance of these moieties.  
34 
 
Current analogue development is focused on improving the pharmacological properties of 
pentalinonsterol itself through the introduction of a hydroxyl handle for the attachment of water 
solubilizing groups as well as mechanistic probes.  We have obtained key methyl ketone 
intermediates from both deoxycholic acid and chenodeoxycholic acid and have successfully 
performed the alkylation on silyl protected material.  We are optimistic about the success of the 
Wittig olefination once we acquire more material to investigate reaction conditions.  A-ring 
functionalization will then provide the hydroxyl containing analogues, a sequence for which we 
have literature precedence; selective C3 alcohol deprotection, oxidation to the ketone, and IBX 
oxidation to install the -unsaturated ketone.  With these analogues in hand we hope to learn 
more about pentalinonsterol’s mechanism of action and improve its oral bioavailability.  
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Chapter 5:  Experimentals  
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Note about Sterol Characterization: Not all protons present in the molecules synthesized are 
listed in the 
1
H NMR characterization data due to the difficulty in interpreting the aliphatic 
region (between 0.5 and 2.5 ppm) of this class of compounds.  Chemical shifts are reported for 
proton NMR peaks considered to be of diagnostic value in accordance with examples in the 
chemical literature.  Specifically, this includes any peaks occurring downfield of 2.5 ppm as well 
as methyl groups observed from 0-2.5 ppm. 
   
 
Silyl ether 8. A solution of pregnenolone (3.000 g, 9.749 mmol), tert-butyldimethylsilyl chloride 
(2.143 g, 14.21 mmol), and imidazole (0.807 g, 11.85 mmol) in DMF (158 mL) was stirred at 21 
C overnight.  The reaction mixture was quenched with cold deionized water.  The resulting 
white precipitate was collected via vacuum filtration and washed with cold deionized water (3 x 
10 mL) to obtain the silyl ether 8 (3.896 g, 9.045 mmol, 95%) as a white powder: mp 163 °C; 
1
H 
NMR (400 MHz, CDCl3) δ 5.31 (m, 1H), 3.48 (m, 1H), 2.53 (t, J = 8.9 Hz, 1H), 2.12 (s, 3H), 
1.81 (dt, J = 13.2, 3.4 Hz, 1H), 0.98 (s, 3H), 0.88 (s, 9H), 0.62 (s, 3H), 0.05 (s, 6H); 13C NMR 
(100 MHz, CDCl3) δ 209.74, 141.69, 121.01, 72.68, 63.87, 57.10, 50.20, 44.16, 42.90, 39.01, 
37.52, 36.74, 32.18, 32.00, 31.95, 31.71, 26.08, 24.63, 22.94, 21.21, 19.56, 18.41, 13.36, -4.44; 
IR (film): 1701 cm−1; HRMS-TOF m/z (M + Na)+ calcd for C27H46O2Si 453.3165, found 
453.3165.  
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Mono-alkylated silyl ether 9. To a solution of tetramethylpiperidine (0.296 mL, 1.741 mmol) in 
THF (5.7 mL) at -78 C was added n-butyl lithium (2.5 M in hexanes, 0.650 mL, 1.625 mmol).  
The resulting solution was allowed to stir for 35 minutes at -78 C before the addition of a 
solution of 8 (0.500 g, 1.161 mmol) in THF (5.7 mL).  After 3 h of stirring at -78 C, dimethyl 
allyl bromide (0.268 mL, 2.321 mmol) was added dropwise to the reaction mixture, warmed to 
21 C, and stirred overnight.   The reaction was quenched with excess aqueous ammonium 
chloride.  The organic layer was removed and the aqueous layer was extracted three times with 
ethyl acetate.  The combined organic layers were then dried with anhydrous sodium sulfate and 
concentrated under reduced pressure.  The crude product was purified by silica gel column 
chromatography (EtOAc:DCM:hexanes, 1:1:98) to afford pure mono-alkylated product 9 (0.397 
g, 0.796 mmol, 68%) as a white solid: mp 120-121 °C; 
1
H NMR (300 MHz, CDCl3) δ 5.31 (d, J 
= 5.2 Hz, 1H), 5.08 (t, 1H), 3.48 (m, 1H), 2.51 (t, J = 8.9 Hz, 1H), 1.66 (s, 3H), 1.60 (s, 3H), 
1.00 (s, 3H), 0.88 (s, 9H), 0.61 (s, 3H), 0.06 (s, 6H); 
13
C NMR (101 MHz, CDCl3) δ 211.32, 
141.65, 132.51, 123.33, 121.00, 72.66, 63.07, 57.14, 50.22, 44.44, 44.32, 42.90, 39.11, 37.52, 
36.73, 32.18, 32.00, 31.96, 26.06, 25.81, 24.67, 23.06, 22.56, 21.21, 19.55, 18.37, 17.78, 13.48, -
4.46; IR (film): 1704 cm−1; HRMS-TOF m/z (M + Na)+ calcd for C32H54O2Si 521.3791, found 
521.3814. 
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Methylene 10. To a solution of methyltriphenylphosphonium bromide (3.940 g, 11.02 mmol) in 
THF (5.5 mL) at 0 C was added n-butyl lithium (2.5 M in hexanes, 4.19 mL, 10.47 mmol).  The 
resulting reaction mixture was stirred at 0 C for 1 hour before adding a solution of 9 (0.550 g, 
1.102 mmol) in THF (5.5 mL).  The reaction was brought to reflux and stirred overnight before 
being quenched with deionized water.  The organic layer was removed and the aqueous layer 
was extracted three times with ethyl acetate.  Combined organic layers were dried over 
anhydrous sodium sulfate and concentrated under reduced pressure.   The crude mixture was 
then purified via silica gel column chromatography (EtOAc-hexanes, 2:98) to obtain pure 10 
(0.489 g, 0.984 mmol, 89%) as a white solid:   mp 86 °C; 
1
H NMR (400 MHz, CDCl3) δ 5.32 (d, 
J = 5.2 Hz, 1H), 5.11 (m, 1H), 4.88 (s, 1H), 4.79 (s, 1H), 3.48 (m, 1H), 2.27 (t, J = 12.0 Hz, 1H), 
1.68 (s, 3H), 1.61 (s, 3H), 0.99 (s, 3H), 0.87 (s, 9H), 0.57 (s, 3H), 0.06 (s, 6H); 
13
C NMR (101 
MHz, CDCl3) δ 149.49, 141.76, 131.58, 124.53, 121.23, 109.54, 72.76, 72.00, 56.84, 56.15, 
50.50, 43.24, 42.96, 38.88, 37.84, 37.54, 36.79, 32.45, 32.22, 32.01, 27.30, 26.09, 25.99, 25.87, 
24.38, 21.27, 19.61, 18.43, 17.88, 12.90, -4.44; IR (film): 2928 cm−1.  
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,γ-alcohol 11. A solution of 10 (0.124 g, 0.250 mmol) and tetrabutylammonium fluoride (1.0 M 
in THF, 0.5 mL, 0.5 mmol) in THF (1.25 mL) was stirred at 21 C overnight.  The reaction 
mixture was concentrated under reduced pressure and the resulting residue was purified by silica 
gel column chromatography (EtOAc-DCM-hexanes, 1:4:5) to give the corresponding β,γ-alcohol 
11 (0.094 g, 0.246 mmol, 94%) as a white solid: mp 89-91 °C; 
1
H NMR (400 MHz, CDCl3) δ 
5.36 (d, J = 5.1 Hz, 1H), 5.11 (m, 1H), 4.88 (s, 1H), 4.79 (s, 1H), 3.53 (m, 1H), 1.69 (s, 3H), 1.58 
(s, 3H), 0.99 (s, 3H), 0.58 (s, 3H); 
13
C NMR (101 MHz, CDCl3) δ 149.45, 140.93, 131.59, 
124.52, 121.78, 109.56, 72.00, 71.92, 56.79, 56.14, 50.40, 43.22, 42.43, 38.85, 37.84, 37.40, 
36.69, 32.43, 31.96, 31.79, 27.30, 25.98, 25.87, 24.37, 21.28, 19.57, 17.87, 12.91; HRMS-TOF 
m/z (M + Na)+ calcd for C27H42O 405.3133, found 405.3151. 
 
 
,γ-alcohol 53. A solution of 9 (0.090 g, 0.180 mmol) and tetrabutylammonium fluoride (1.0 M 
in THF, 0.271 mL, 0.271 mmol) in THF (0.902 mL) was stirred at 21 C overnight.  The reaction 
mixture was concentrated under reduced pressure and the resulting residue was purified by silica 
gel column chromatography (acetone-hexanes, 5:95) to give the corresponding β,γ-alcohol 53 
(0.059 g, 0.153 mmol, 85%) as a white solid: 
1
H NMR (250 MHz, CDCl3) δ 5.34 (d, 1H), 5.06 
(m, 1H), 3.52 (m, 1H), 1.67 (s, 3H), 1.61 (s, 3H), 1.00 (s, 3H), 0.61 (s, 3H).   
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Pentalinonsterol (1). To a solution of 11 (0.434 g, 1.135 mmol) and cyclohexanone (1.175 mL, 
11.35 mmol) in toluene (22.7 mL) at reflux was added aluminum isopropoxide (0.116 g, 0.568 
mmol).  The reaction was stirred at reflux overnight.  The reaction mixture was concentrated 
under reduced pressure, taken up in deionized water, and extracted three times with ethyl acetate.  
The crude mixture was purified by silica gel column chromatography (EtOAc:hexanes, gradient 
7-10% EtOAc, 1% EtOAc every 100 mL) to afford pure pentalinonsterol (1) (0.386 g, 1.014 
mmol, 89%) as a white solid: mp 89-91 °C; 
1
H NMR (400 MHz, CDCl3) δ 5.73 (s, 1H), 5.10 (m, 
1H), 4.89 (s, 1H), 4.79 (s, 1H), 1.68 (s,3H), 1.60 (s, 3H), 1.16 (s, 3H), 0.61 (s, 3H); 
13
C NMR 
(101 MHz, CDCl3) δ 199.83, 171.75, 149.18, 131.66, 124.42, 123.93, 109.82, 72.00, 56.05, 
55.90, 54.08, 43.25, 38.79, 38.67, 37.78, 36.16, 35.84, 34.12, 33.06, 32.09, 27.28, 25.92, 25.86, 
24.25, 21.23, 17.87, 17.54, 13.00; HRMS-TOF m/z (M + Na)+ calcd for C27H42O 405.3133, 
found 405.3151. 
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α,β-unsaturated ketone 14. To a solution of 53 (0.057 g, 0.147 mmol) and cyclohexanone 
(0.153 mL, 1.474 mmol) in toluene (2.95 mL) at reflux was added aluminum isopropoxide 
(0.015 g, 0.074 mmol).  The reaction was stirred at reflux overnight.  The reaction mixture was 
concentrated under reduced pressure, taken up in deionized water, and extracted three times with 
ethyl acetate.  The crude mixture was purified by silica gel column chromatography (acetone-
hexanes, 5:95) to afford pure 14 (0.049 g, 0.128 mmol, 87%) as a clear oil: 
1
H NMR (300 MHz, 
CDCl3) δ 5.71 (s, 1H), 5.04 (t, J = 6.8 Hz, 1H), 1.67 (s, 3H), 1.59 (s, 3H), 1.15 (s, 3H), 0.63 (s, 
3H).
 
 
 
Allyl alcohols 12 and 13. A solution of pentalinonsterol (1) (0.030, 0.079 mmol) and cerium 
(III) chloride heptahydrate (0.029 g, 0.079 mmol) in THF-MeOH (2:1, 0.790 mL) was cooled to 
0 C before the portion wise addition of sodium borohydride (0.019 g, 0.502 mmol).  The 
reaction mixture was allowed to warm to 21 C and stirred overnight.  The reaction was 
quenched with 2M HCl.  The organic layer was removed and the aqueous layer was extracted 
three times with ethyl acetate.  Combined organic layers were washed with brine, dried over 
anhydrous sodium sulfate, and concentrated under reduced pressure.   The crude mixture was 
then purified via silica gel column chromatography (EtOAc:hexanes, gradient 5-10% EtOAc, 1% 
EtOAc every 100 mL) to afford two diastereomers (d.r. 3.4:1, 56% overall yield): 
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(0.013 g, 0.034 mmol, 43%) as a white solid: 
1
H NMR (400 MHz, CDCl3) δ 5.28 (s, 1H), 5.11 (s, 
1H), 4.88 (s, 1H), 4.78 (s, 1H), 4.14 (s, 1H), 1.68 (s, 3H), 1.61 (s, 3H), 1.07 (s, 3H), 0.58 (s, 3H); 
13
C NMR (101 MHz, CDCl3) δ 149.46, 147.86, 131.57, 124.53, 123.51, 109.62, 68.13, 56.24, 
56.20, 54.77, 43.37, 38.94, 37.81, 37.55, 36.53, 35.54, 33.20, 32.36, 29.69, 27.32, 25.98, 25.85, 
24.31, 21.26, 19.11, 17.86, 13.03; IR (film): 3330, 2930, 2849 cm
-1
.     
 
(0.004 g, 0.010 mmol, 13%) as a white solid: 
1
H NMR (250 MHz, CDCl3) δ 5.47 (d, J = 4.7 Hz, 
1H), 5.12 (s, 1H), 4.88 (s, 1H), 4.79 (s, 1H), 4.07 (s, 1H), 1.69 (s, 5H), 1.61 (s, 4H), 0.98 (s, 3H), 
0.59 (s, 3H). 
 
 
General procedure for acylation: 
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 To a solution of a cholic acid derivative in acetic anhydride (23 equiv.) at 0 C was added 
dimethylaminopyridine (0.06 equiv.) and triethylamine (16 equiv.).  The resulting reaction 
mixture was stirred at 21 C overnight.  The reaction was quenched with deionized water at 0 C.  
The organic layer was removed and the aqueous layer was extracted three times with ethyl 
acetate.  Combined organic layers were washed with 1 M HCl and deionized water before being 
dried over anhydrous sodium sulfate and concentrated under reduced pressure.  The crude 
product was then dissolved in a THF-H2O, 4:1 solution and refluxed overnight.  The organic 
layer was removed and the aqueous layer was extracted three times with ethyl acetate.  
Combined organic layers were concentrated under reduced pressure.  The crude mixture was 
purified via silica gel column chromatography (EtOAc-hexanes, 33:67) to obtain the 
corresponding products. 
 
Acylated deoxycholic acid 26. Using deoxycholic acid (18) (1.500 g, 3.82 mmol) as the starting 
material, the above general procedure afforded compound  26 (1.928 g, 3.606 mmol, 94%), 
obtained as a white solid: 
1
H NMR (400 MHz, CDCl3) δ 5.08 (s, 1H), 4.70 (m, 1H), 2.10 (s, 3H), 
2.03 (s, 3H), 0.89 (s, 3H), 0.81 (d, J = 6.3 Hz, 3H), 0.73 (s, 3H); 
13
C NMR (101 MHz, CDCl3) δ 
179.85, 170.77, 170.65, 76.06, 74.37, 49.59, 47.73, 45.18, 41.97, 35.83, 34.87, 34.80, 34.55, 
34.19, 32.41, 31.03, 30.75, 27.47, 27.03, 26.78, 26.01, 25.79, 23.57, 23.21, 21.60, 21.51, 17.64, 
12.56; IR (film): 2946, 2870, 1735 cm
-1
.   
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Acylated chenodeoxycholic acid 27. Using chenodeoxycholic acid (19) (3.000 g, 7.642 mmol) 
as the starting material, the above general procedure afforded 27 (2.794 g, 5.862 mmol, 77%) as 
a white solid: 
1
H NMR (400 MHz, CDCl3) δ 4.87 (s, 1H), 4.58 (m, 1H), 2.04 (s, 3H), 2.02 (s, 
3H), 0.928 (d, J = 6.3 Hz, 3H), 0.925 (s, 3H), 0.65 (s, 3H); 
13
C NMR (101 MHz, CDCl3) δ 
179.92, 170.83, 170.62, 74.34, 71.40, 55.88, 50.54, 42.85, 41.09, 39.64, 38.04, 35.36, 35.04, 
34.93, 34.77, 34.21, 31.46, 31.00, 30.84, 28.14, 26.93, 23.68, 22.82, 21.72, 21.61, 20.79, 18.39, 
11.85; IR (film): 2941, 2871, 1733 cm
-1
.   
 
General procedure for sulphine formation:  
To a solution of an acylated cholic derivative and pyridine (10 equiv.) in DCM (0.2 M) at 10 C 
was added thionyl chloride (2.2 equiv.).  The reaction was allowed to stir 30 minutes at 21 C 
before being cooled to 0 C for the addition of excess methanol (1 M).  The reaction mixture was 
stirred for 10 minutes at 0 C before being quenched with 0.5 M HCl (0.05 M).  The organic 
layer was removed and the aqueous layer was extracted three times with DCM.  Combined 
organic layers were dried with anhydrous sodium sulfate and concentrated under reduced 
pressure.  The crude mixture was purified via silica gel column chromatography (EtOAc-
hexanes, 13:87) to afford the corresponding products. 
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Sulphine 28. Using acylated deoxycholic acid 26 (0.500 g, 1.048 mmol) as the starting material, 
the above general procedure afforded sulphine 28 (0.286 g, 0.533 mmol, 51%) as a white 
powder: 
1
H NMR (400 MHz, CDCl3) δ 5.04 (s, 1H), 4.68 (m, 1H), 3.84 (s, 3H), 2.87 (dd, J = 
12.5, 10.2 Hz, 1H), 2.70 (d, J = 12.4 Hz, 1H), 2.09 (s, 3H), 2.02 (s, 3H), 0.89 (s, 3H), 0.77 (d, J = 
5.6 Hz, 3H), 0.72 (s, 3H); 
13
C NMR (101 MHz, CDCl3) δ 186.67, 170.68, 170.55, 164.22, 75.76, 
74.27, 52.79, 49.61, 48.71, 45.42, 41.91, 36.07, 35.79, 34.82, 34.45, 34.36, 34.13, 32.36, 27.53, 
26.97, 26.74, 25.94, 25.71, 23.58, 23.18, 21.59, 21.57, 18.04, 12.58. 
 
Sulphine 29. Using acylated chenodeoxycholic acid 27 (0.330 g, 0.692 mmol) as the starting 
material, the above general procedure afforded sulphine 29 (0.167 g, 0.311mmol, 45%) as a 
white powder: 
1
H NMR (400 MHz, CDCl3) δ 4.89 (s, 1H), 4.59 (m, 1H), 3.85 (s, 3H), 2.91 (dd, J 
= 12.6, 10.8 Hz, 1H), 2.71 (dd, J = 12.8, 3.2 Hz, 1H), 2.06 (s, 3H), 2.03 (s, 3H), 0.93 (s, 3H), 
0.91 (d, J = 6.6 Hz, 3H), 0.66 (s, 3H); 
13
C NMR (101 MHz, CDCl3) δ 186.91, 170.78, 170.56, 
164.30, 74.29, 71.33, 57.01, 52.79, 50.61, 43.18, 41.10, 39.51, 38.06, 36.90, 35.05, 34.95, 34.79, 
34.64, 34.18, 31.47, 28.34, 26.94, 23.77, 22.83, 21.75, 21.63, 20.76, 18.68, 11.86; IR (film): 
2941, 2870, 1731 cm
-1
. 
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General procedure for α-ketoester formation: 
To a sulphine was added a prepared solution (0.56 M) of acetic anhydride (1.15 mL) and sulfuric 
acid (35 µL, 95%) in DCM (8.8 mL).  The resulting reaction mixture was stirred at 21 C for 15 
minutes before dilution with DCM (0.05 M) and potassium carbonate (0.11 M, 5% w/v).  The 
reaction was stirred overnight and then quenched with deionized water.  The organic layer was 
removed and the aqueous layer was extracted three times with DCM.  Combined organic layers 
were washed with brine, dried over anhydrous sodium sulfate, and concentrated under reduced 
pressure.  The crude mixture was purified via silica gel column chromatography (EtOAc-
hexanes, 15:85) to afford the corresponding products.  
 
α-ketoester 30. Using sulphine 28 (0.500 g, 0.932 mmol) as the starting material, the above 
general procedure afforded α-ketoester 30 (0.396 g, 0.785 mmol, 84%) as a white solid: 1H NMR 
(400 MHz, CDCl3) δ 5.05 (s, 1H), 4.68 (m, 1H), 3.84 (m, 3H), 2.85 (dd, J = 17.1, 3.1 Hz, 1H), 
2.59 (dd, J = 17.1, 9.3 Hz, 1H), 2.10 (s, 3H), 2.01 (s, 3H), 0.89 (s, 3H), 0.84 (d, J = 6.5 Hz, 3H), 
0.75 (s, 3H); 
13
C NMR (101 MHz, CDCl3) δ 194.26, 170.65, 170.50, 161.89, 75.80, 74.28, 
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53.03, 49.63, 47.62, 46.03, 45.25, 41.93, 35.79, 34.84, 34.50, 34.16, 32.39, 31.83, 27.77, 26.98, 
26.75, 25.96, 25.74, 23.53, 23.18, 21.56, 21.48, 18.98, 12.50.   
 
α-ketoester 31. Using sulphine 29 (0.500g, 0.932 mmol) as the starting material, the above 
general procedure afforded α-ketoester 31 (0.311 g, 0.616 mmol, 66%) as a white solid: 1H NMR 
(400 MHz, CDCl3) δ 4.88 (d, J = 2.4 Hz, 1H), 4.58 (m, 1H), 3.86 (s, 3H), 2.89 (dd, J = 16.8, 3.0 
Hz, 1H), 2.58 (dd, J = 16.9, 9.7 Hz, 1H), 2.05 (s, 3H), 2.03 (s, 3H), 0.96 (d, J = 6.5 Hz, 3H), 0.93 
(s, 3H), 0.69 (s, 3H); 
13
C NMR (101 MHz, CDCl3) δ 194.51, 170.76, 170.53, 161.94, 74.29, 
71.31, 56.04, 53.05, 50.60, 46.28, 42.99, 41.09, 39.53, 38.05, 35.04, 34.95, 34.79, 34.20, 32.41, 
31.47, 28.41, 26.94, 23.69, 22.82, 21.72, 21.63, 20.76, 19.81, 11.87; IR (film): 2940, 2871, 1732 
cm
-1
. 
 
General procedure for methyl ketone formation:  
A solution of an α-ketoester, 1,4-diazabicyclo[2.2.2]octane (0.044 g, 0.392 mmol), cupric acetate 
(0.031 g, 0.157 mmol), and 2,2’-dipyridyl (0.029 g, 0.188 mmol) in DMF (26.1 mL) was stirred 
at 50 C open to the atmosphere for 6.5 days.  The reaction mixture was then cooled to 0 C and 
quenched with deionized water.  The organic layer was removed and the aqueous layer was 
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extracted three times with DCM.  Combined organic layers were washed with brine, dried over 
anhydrous sodium sulfate, and concentrated under reduced pressure.  The crude mixture was 
purified via silica gel column chromatography (EtOAc-hexanes, 15:85) to afford the 
corresponding products. 
 
Methyl ketone 25. Using α-ketoester 30 (0.396 g, 0.785 mmol)  as the starting material, the 
above general procedure afforded methyl ketone 25 (0.297 g, 0.710 mmol, 90%) as a white solid: 
1
H NMR (300 MHz, CDCl3) δ 5.11 (s, 1H), 4.67 (m, 1H), 2.93 (t, J = 8.9 Hz, 1H), 2.14 (s, 3H), 
2.01 (s, 3H), 1.99 (s, 3H), 0.88 (s, 3H), 0.65 (s, 3H); 
13
C NMR (101 MHz, CDCl3) δ 208.90, 
170.67, 170.54, 74.62, 74.23, 55.76, 49.78, 46.87, 41.91, 35.77, 34.90, 34.62, 34.25, 32.41, 
31.24, 26.95, 26.78, 26.05, 25.78, 23.82, 23.17, 22.44, 21.60, 21.55, 14.00. 
 
Methyl ketone 32. Using α-ketoester 31 (0.174 g, 0.345 mmol)  as the starting material, the 
above general procedure afforded methyl ketone 32 (0.135 g, 0.323 mmol, 93%) as a white solid: 
1
H NMR (400 MHz, CDCl3) δ 4.86 (s, 1H), 4.56 (m, 1H), 2.50 (t, J = 9.3 Hz, 1H), 2.08 (s, 3H), 
2.02 (s, 3H), 2.00 (s, 3H), 0.90 (s, 3H), 0.57 (s, 3H). 
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General procedure for acetate deprotection: 
A solution of a methyl ketone and potassium carbonate (5 equiv.) in methanol (0.05 M) was 
stirred at 50 C for 24 h.  The reaction mixture was concentrated under reduced pressure, taken 
up in deionized water, and extracted with EtOAc three times.  The combined organic layers were 
washed with brine, dried over anhydrous sodium sulphate, and concentrated under reduced 
pressure to yield the corresponding products. 
 
Deoxycholic methyl ketone 33. Using methyl ketone 25 (0.109 g, 0.261 mmol)  as the starting 
material, the above general procedure afforded crude deoxycholic methyl ketone 33 (0.074 g) as 
a white solid.  The crude product was checked by proton NMR and then carried forward into the 
next reaction without further purification: 
1
H NMR (300 MHz, CDCl3) δ 3.98 (t, J = 2.8 Hz, 1H), 
3.63 (m, 1H), 3.12 (t, J = 9.3 Hz, 1H), 2.14 (s, 3H), 0.91 (s, 3H), 0.63 (s, 3H). 
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Chenodeoxycholic methyl ketone 34. Using methyl ketone 32 (0.110 g, 0.263 mmol) as the 
starting material, the above general procedure afforded crude chenodeoxycholic methyl ketone 
34 (0.078 g) as a white solid.  Existence of desired product was confirmed by proton NMR. 
 
 
Di-silyl ether 35. A solution of crude deoxycholic methyl ketone 33 (0.073 g), tert-
butyldimethylsilyl chloride (9.5 equiv.), and imidazole (10 equiv.) in DMF (0.05 M) was stirred 
at 80 C overnight.  The reaction mixture was quenched with deionized water.  The organic layer 
was removed and the aqueous layer was extracted three times with DCM.  Combined organic 
layers were washed with brine, dried over anhydrous sodium sulfate, and concentrated under 
reduced pressure.  The crude mixture was purified via silica gel column chromatography 
(EtOAc-hexanes, 2:98) to afford pure di-silyl ether 35 (0.078 g, 0.139 mmol, 53% over 2 steps) 
as a white solid: ( 
1
H NMR (400 MHz, CDCl3) δ 4.10 (s, 1H), 3.54 (m, 1H), 2.93 (t, J = 9.9 Hz, 
1H), 2.05 (s, 3H), 0.92 (s, 9H), 0.87 (s, 3H), 0.87 (s, 9H), 0.70 (s, 3H), 0.06 (s, 3H), 0.02 (s, 6H), 
-0.01 (s, 3H);  
13
C NMR (101 MHz, CDCl3) δ 210.47, 72.51, 72.38, 55.65, 47.86, 47.56, 42.41, 
37.27, 35.92, 35.54, 34.41, 33.81, 31.39, 30.58, 28.38, 27.52, 26.36, 26.29, 26.01, 24.15, 23.94, 
23.56, 18.37, 18.19, 13.94, -3.58, -4.36, -4.74; IR (film): 2952, 2927, 2857, 1703 cm
-1
.   
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Mono-alkylated di-silyl ether 37. To a solution of tetramethylpiperidine (0.034 mL, 0.202 
mmol) in THF (0.63 mL) at -78 C was added n-butyl lithium (2.5 M in hexanes, 0.076 mL, 
0.189 mmol).  The resulting solution was allowed to stir for 35 minutes at -78 C before the 
addition of a solution of di-silyl ether 35 (0.071 g, 0.126 mmol) in THF (0.63 mL).  After 1 h of 
stirring at -78 C, dimethyl allyl bromide (0.029 mL, 0.252 mmol) was added drop wise to the 
reaction mixture, warmed to 21 C, and stirred overnight.   The reaction was quenched with 
excess aqueous ammonium chloride.  The separated and aqueous layer was extracted with ethyl 
acetate.  The combined organic layers were then dried with anhydrous sodium sulfate and 
concentrated under reduced pressure.  The presence of mono-alkylated di-silyl ether 37 in the 
crude material was confirmed by proton NMR, but the purity of the compound is not sufficient 
for complete compound characterization. 
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Appendix: Characterization Data of Selected Compounds 
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